首页> 美国卫生研究院文献>BioMed Research International >Systemic Sclerosis Pathogenesis and Emerging Therapies, beyond the Fibroblast
【2h】

Systemic Sclerosis Pathogenesis and Emerging Therapies, beyond the Fibroblast

机译:除成纤维细胞外,系统性硬化病的发病机理和新兴疗法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Systemic sclerosis (SSc) is a complex rheumatologic autoimmune disease in which inflammation, fibrosis, and vasculopathy share several pathogenic pathways that lead to skin and internal organ damage. Recent findings regarding the participation and interaction of the innate and acquired immune system have led to a better understanding of the pathogenesis of the disease and to the identification of new therapeutic targets, many of which have been tested in preclinical and clinical trials with varying results. In this manuscript, we review the state of the art of the pathogenesis of this disease and discuss the main therapeutic targets related to each pathogenic mechanism that have been discovered so far.
机译:系统性硬化症(SSc)是一种复杂的风湿性自身免疫疾病,其中炎症,纤维化和血管病变共有几种致病性途径,导致皮肤和内部器官受损。有关先天和后天免疫系统参与和相互作用的最新发现,导致人们对该疾病的发病机理有了更好的了解,并确定了新的治疗靶标,其中许多已经在临床前和临床试验中进行了测试,结果各不相同。在这份手稿中,我们回顾了这种疾病的发病机理,并讨论了迄今为止已发现的与每种致病机制相关的主要治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号